Share
Share today's newsletter with a colleague and get credit if they sign up for SmartBrief.
Referral Count:
 
0

Story being shared
Pfizer halts development of hep C drug filibuvir
Pfizer said it would stop developing its midstage hepatitis C drug filibuvir, or PF-00868554. Potential competitors included new hepatitis C therapies from Gilead Sciences and AbbVie. "We continue to prioritize our [research and development] capital allocation to drive the next wave of innovative medicines and vaccines that bring benefit to patients and value to health care systems around the world," Pfizer's Victoria Davis said.

Or we can send an email on your behalf
You must submit valid email addresses only. Use of email addresses is subject to terms of SmartBrief's privacy policy .